VANCOUVER, BRITISH COLUMBIA--(Marketwire - November 19, 2007) - Pacgen Biopharmaceuticals Corporation ("Pacgen") (TSX VENTURE: PGA) has initiated a Phase IIb dose-ranging clinical trial for an optimized formulation of PAC-113, a novel treatment for oral Candidiasis infection. This study will be a randomized, examiner-blinded, parallel design trial comparing three different doses of PAC-113 to Nystatin. Nystatin is a widely used, topical mouth rinse treatment for oral Candidiasis.
